Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines

Genocea shows targeting inhibitor neoantigens can abrogate vaccine-mediated protection

Genocea’s SITC presentations bolstered its case for screening out inhibitory neoantigens from cancer vaccines by suggesting the peptides play a role in checkpoint inhibitor resistance and promote disease progression.

One of the keys to designing effective personalized cancer vaccines is the

Read the full 403 word article

User Sign In